{
    "nct_id": "NCT04873362",
    "official_title": "A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy",
    "inclusion_criteria": "* Histologically confirmed invasive breast carcinoma\n* Centrally-confirmed human epidermal growth factor receptor 2 (HER2)-positive invasive breast cancer\n* Centrally confirmed PD-L1 and hormone receptor status\n* Clinical stage at disease presentation (prior to neoadjuvant therapy): cT4/anyN/M0, any cT/N2-3/M0, or cT1-3/N0-1/M0 (participants with cT1mi/T1a/T1b/N0 are not eligible)\n* Completion of pre-operative systemic chemotherapy including at least 9 weeks of taxane and 9 weeks of trastuzumab (anthracycline and/or additional HER2-targeted agents are permitted)\n* <=12 weeks between primary surgery and randomization\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1\n* Screening left ventricular ejection fraction (LVEF) >= 50% and no decrease in LVEF by >15% from the pre-chemotherapy LVEF. If no pre-chemotherapy LVEF, screening LVEF >= 55%\n* Life expectancy >= 6 months\n* Adequate hematologic and end organ function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Stage IV breast cancer\n* An overall response of disease progression according to the investigator at the conclusion of preoperative systemic therapy\n* Prior treatment with T-DM1, or atezolizumab, or other immune checkpoint inhibitors\n* History of exposure to various cumulative doses of anthracyclines\n* History of other malignancy within 5 years prior to screening, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or ductal carcinoma in situ (DCIS)\n* Current grade >=2 peripheral neuropathy\n* History of idiopathic pulmonary fibrosis, organizing pneumonia, or pneumonitis\n* History of or active autoimmune disease or immune deficiency\n* Treatment with immunostimulatory or immunosuppressive agents\n* Cardiopulmonary dysfunction\n* Any known active liver disease",
    "miscellaneous_criteria": ""
}